Evidence map›Paper›PMID 41053323›Full record

ArticleJournal of natural medicines2025

Development of a low-cost, simple, and rapid identification method for Glycyrrhiza uralensis using PCR-RFLP and evaluation of seeds distributed on the market.

Tomoyo Nishida, Shinichiro Sawa, Koji Sugimura

Abstract read
In one paragraph

Article in Journal of natural medicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tomoyo NishidaGlobal Center for Natural Resources Sciences, Kumamoto University, 5-1, Oe Honmachi, Chuo-Ku, Kumamoto, 862-0973, Japan.
Shinichiro SawaInternational Research Center for Agricultural and Environmental Biology, Kumamoto University, 2-39-1, Kumamoto, Japan.
Koji SugimuraGlobal Center for Natural Resources Sciences, Kumamoto University, 5-1, Oe Honmachi, Chuo-Ku, Kumamoto, 862-0973, Japan. sugimura@kumamoto-u.ac.jp.ORCID http://orcid.org/0000-0002-4507-5749

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycyrrhiza is a crude drug used worldwide, especially in China and Japan. Glycyrrhiza uralensis Fischer and Glycyrrhiza glabra L. are listed as original plants in the 18th revised Japanese Pharmacopoeia; however, G. uralensis is considered the most important Glycyrrhiza species because it has traditionally been used medicinally. Most G. uralensis used in Japan is imported from China, but export restrictions in recent years have raised concerns about stable supply. Therefore, domestic cultivation in Japan is expected to prevent price increases of raw materials and ensure a stable supply. Accurate species identification is an important step in quality control. In recent years, a method for identifying species using molecular markers has been evaluated for the Glycyrrhiza genus; however, in this study, we found that a simpler method, PCR-RFLP, using two types of restriction enzymes, can be used to identify G. uralensis more cheaply and easily than conventional methods. When applied to the ITS1-5.8S-ITS2 region, the analysis of seeds distributed in the market showed that only four of the 190 seeds surveyed were G. uralensis, while most were G. glabra, G. inflata, or their hybrids. Therefore, to appropriately use commercially available G. uralensis seeds, it is important to correctly identify the species at an early stage. Quick identification using PCR-RFLP is thought to be a useful method for ensuring the adequate supply of G. uralensis.

Indexed as

Glycyrrhiza uralensisPolymerase Chain ReactionPolymorphism, Restriction Fragment LengthSeedsDNA, PlantDNA, PlantGenetic markersGlycyrrhiza uralensisHybridizationPCR–RFLPSpecies identification

Identifiers

PMID41053323
PMCPMC12620321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.